CY1120856T1 - Μεθοδοι παραδοσης γονιδιων - Google Patents

Μεθοδοι παραδοσης γονιδιων

Info

Publication number
CY1120856T1
CY1120856T1 CY181101198T CY181101198T CY1120856T1 CY 1120856 T1 CY1120856 T1 CY 1120856T1 CY 181101198 T CY181101198 T CY 181101198T CY 181101198 T CY181101198 T CY 181101198T CY 1120856 T1 CY1120856 T1 CY 1120856T1
Authority
CY
Cyprus
Prior art keywords
plasmids
transgens
transgene
target cells
gene delivery
Prior art date
Application number
CY181101198T
Other languages
English (en)
Inventor
Linda May Rothblum Watkins
Travis Hughes
Raymond A Chavez
Original Assignee
Univ Colorado Regents
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Colorado Regents filed Critical Univ Colorado Regents
Publication of CY1120856T1 publication Critical patent/CY1120856T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Περιγράφονται μέθοδοι παράδοσης διαγονιδίων σε κύτταρα-στόχους χρησιμοποιώντας πλασμίδια που περιλαμβάνουν ιικές ανεστραμμένες τερματικές επαναλαμβανόμενες αλληλουχίες (ITR). Τέτοια πλασμίδια είναι ικανά να οδηγούν παρατεταμένη έκφραση διαγονιδίων σε κύτταρα-στόχους σε αρουραίους υπό την προϋπόθεση ότι τουλάχιστον μία αλληλουχία ITR αδενοσχετιζόμενου ιού (AAV) είναι παρούσα στο πλασμίδιο, ανεξάρτητα από το εάν η ITR βρίσκεται ανοδικά ή καθοδικά του διαγονιδίου. Σε συγκεκριμένη υλοποίηση, επιδεικνύεται ότι πλασμίδια που περιλαμβάνουν μία ή περισσότερες αλληλουχίες AAV ITR και διαγονίδιο IL-10 είναι αποτελεσματικά σε παρατεταμένη αντιστροφή πόνου σε ζωικό πρότυπο νευροπαθούς πόνου.
CY181101198T 2005-05-31 2018-11-13 Μεθοδοι παραδοσης γονιδιων CY1120856T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US68632405P 2005-05-31 2005-05-31
PCT/US2006/020864 WO2006130581A2 (en) 2005-05-31 2006-05-26 Methods for delivering genes
EP06771554.0A EP1885863B1 (en) 2005-05-31 2006-05-26 Methods for delivering genes

Publications (1)

Publication Number Publication Date
CY1120856T1 true CY1120856T1 (el) 2019-12-11

Family

ID=37420968

Family Applications (1)

Application Number Title Priority Date Filing Date
CY181101198T CY1120856T1 (el) 2005-05-31 2018-11-13 Μεθοδοι παραδοσης γονιδιων

Country Status (12)

Country Link
US (2) US8524678B2 (el)
EP (2) EP2816118B1 (el)
CY (1) CY1120856T1 (el)
DK (1) DK2816118T3 (el)
ES (1) ES2696824T3 (el)
HK (1) HK1117871A1 (el)
HU (1) HUE041875T2 (el)
LT (1) LT2816118T (el)
PL (1) PL2816118T3 (el)
PT (1) PT2816118T (el)
SI (1) SI2816118T1 (el)
WO (1) WO2006130581A2 (el)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7261882B2 (en) * 2003-06-23 2007-08-28 Reagents Of The University Of Colorado Methods for treating neuropathic pain by administering IL-10 polypeptides
US9249425B2 (en) 2011-05-16 2016-02-02 The Trustees Of The University Of Pennslyvania Proviral plasmids and production of recombinant adeno-associated virus
PT3021873T (pt) 2013-07-18 2018-12-10 Univ Colorado Regents Métodos para o tratamento da doença inflamatória da articulação
US20160251680A1 (en) 2013-11-05 2016-09-01 Clontech Laboratories, Inc. Dry transfection compositions and methods for making and using the same
EP3134115A4 (en) 2014-04-25 2017-10-25 The Trustees Of The University Of Pennsylvania Methods and compositions for treating metastatic breast cancer and other cancers in the brain
KR20170034701A (ko) * 2015-09-21 2017-03-29 코오롱생명과학 주식회사 통증 치료용 조성물
US11273227B2 (en) * 2015-10-09 2022-03-15 The Trustees Of The University Of Pennsylvania Compositions and methods useful in treating Stargardt's disease and other ocular disorders
US11672866B2 (en) 2016-01-08 2023-06-13 Paul N. DURFEE Osteotropic nanoparticles for prevention or treatment of bone metastases
US11344629B2 (en) 2017-03-01 2022-05-31 Charles Jeffrey Brinker Active targeting of cells by monosized protocells
CA3075180A1 (en) * 2017-09-08 2019-03-14 Generation Bio Co. Lipid nanoparticle formulations of non-viral, capsid-free dna vectors
BR112020017060A2 (pt) * 2018-02-22 2020-12-15 Generation Bio Co. Expressão controlada de transgenes usando vetores de dna de extremidade fechada (cedna)
BR112023001648A2 (pt) 2020-07-27 2023-04-04 Anjarium Biosciences Ag Moléculas de dna de fita dupla, veículo de entrega e método para preparar uma molécula de dna com extremidade em grampo

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5036006A (en) 1984-11-13 1991-07-30 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5100792A (en) 1984-11-13 1992-03-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US4663161A (en) 1985-04-22 1987-05-05 Mannino Raphael J Liposome methods and compositions
US4871488A (en) 1985-04-22 1989-10-03 Albany Medical College Of Union University Reconstituting viral glycoproteins into large phospholipid vesicles
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US5179022A (en) 1988-02-29 1993-01-12 E. I. Du Pont De Nemours & Co. Biolistic apparatus for delivering substances into cells and tissues in a non-lethal manner
US5693622A (en) 1989-03-21 1997-12-02 Vical Incorporated Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
US6673776B1 (en) 1989-03-21 2004-01-06 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US6214804B1 (en) 1989-03-21 2001-04-10 Vical Incorporated Induction of a protective immune response in a mammal by injecting a DNA sequence
US6217857B1 (en) 1989-06-28 2001-04-17 Schering Corporation Cytokine synthesis inhibitory factor (IL-10) and pharmaceutical compositions thereof
US5231012A (en) 1989-06-28 1993-07-27 Schering Corporation Nucleic acids encoding cytokine synthesis inhibitory factor (interleukin-10)
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US6312680B1 (en) 1990-06-29 2001-11-06 Timothy R. Mosmann Methods of treatment using cytokine synthesis inhibitory factor
WO1992001070A1 (en) 1990-07-09 1992-01-23 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce High efficiency packaging of mutant adeno-associated virus using amber suppressions
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
JP3534749B2 (ja) 1991-08-20 2004-06-07 アメリカ合衆国 アデノウイルスが介在する胃腸管への遺伝子の輸送
US6132419A (en) 1992-05-22 2000-10-17 Genetronics, Inc. Electroporetic gene and drug therapy
US5993434A (en) 1993-04-01 1999-11-30 Genetronics, Inc. Method of treatment using electroporation mediated delivery of drugs and genes
SK150596A3 (en) 1993-07-26 1997-04-09 Schering Corp Agonists and antagonists of human interleukin-10
US6652850B1 (en) * 1993-09-13 2003-11-25 Aventis Pharmaceuticals Inc. Adeno-associated viral liposomes and their use in transfecting dendritic cells to stimulate specific immunity
WO1995024425A1 (en) 1994-03-11 1995-09-14 Board Of Regents, The University Of Texas System Immunomodulatory trichinella substances
WO1996001318A1 (en) 1994-07-05 1996-01-18 Steeno Research Group A/S Immunomodulators
US6410008B1 (en) 1994-12-12 2002-06-25 Beth Israel Hospital Association Chimeric IL-10 proteins and uses thereof
US5549127A (en) 1995-05-03 1996-08-27 Chang; Wen-Hsiung Spring fixing structure for a hairgrip
US5763270A (en) 1995-06-07 1998-06-09 Genemedicine, Inc. Plasmid for delivery of nucleic acids to cells and methods of use
DK0833934T4 (da) 1995-06-15 2012-11-19 Crucell Holland Bv Pakningssystemer til human rekombinant adenovirus til anvendelse ved genterapi
US5753895A (en) 1996-01-16 1998-05-19 Golden Valley Microwave Foods, Inc. Microwave popcorn package with adhesive pattern
JP2001508652A (ja) 1996-12-23 2001-07-03 シェーリング コーポレイション Ｉｌ１０に関連する哺乳動物サイトカイン
US6233483B1 (en) 1997-05-14 2001-05-15 Pacesetter, Inc. System and method for generating a high efficiency biphasic defibrillation waveform for use in an implantable cardioverter/defibrillator (ICD).
US20030044384A1 (en) 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
WO1999047157A1 (en) 1998-03-17 1999-09-23 Schering Corporation Use of il-10 to treat major depressive disorder
AU752658B2 (en) 1998-05-06 2002-09-26 Association Francaise Contre Les Myopathies Use of a nuclease inhibitor or interleukin-10 (IL-10) for the preparation of a therapeutic composition for improving transfection of a polynucleotide into a cell and compositions useful in gene therapy
ES2326893T3 (es) 1998-05-27 2009-10-21 Genzyme Corporation Vectores aav para la fabricacion de medicamentos para administracion potenciada por conveccion.
US6800484B2 (en) 1998-06-24 2004-10-05 Genetronics, Inc. High efficiency transfection based on low electric field strength, long pulse length
US6428985B1 (en) 1998-12-02 2002-08-06 The Regents Of The University Of Michigan Immunosuppressive structural definition of IL-10
CA2353417C (en) 1998-12-03 2008-04-22 Avigen, Inc. Excipients for use in adeno-associated virus pharmaceutical formulations, and pharmaceutical formulations made therewith
CA2361601A1 (en) 1999-02-08 2000-08-10 Cheryl Goldbeck Electrically-mediated enhancement of dna vaccine immunity and efficacy in vivo
US6982089B2 (en) 1999-02-24 2006-01-03 Tact Ip, Llc Cytokine antagonists for neurological and neuropsychiatric disorders
ES2530857T3 (es) 1999-04-28 2015-03-06 Genetics Inst Llc Proteínas GIL-19/AE289 humanas y polinucleótidos que codifican las mismas
US6165754A (en) 1999-06-08 2000-12-26 Cornell Research Foundation, Inc. Method of expressing an exogenous nucleic acid
WO2001016153A1 (en) 1999-09-02 2001-03-08 University Of Medicine And Dentistry Of New Jersey Cytomegalovirus-encoded il-10 homolog
WO2001039600A1 (en) 1999-12-03 2001-06-07 University Of Massachusetts Use of hsp27 as an anti-inflammatory agent
AU2002217929A1 (en) * 2000-11-28 2002-06-11 Sangamo Biosciences, Inc. Modulation of gene expression using insulator binding proteins
CA2361462A1 (en) 2001-11-07 2003-05-08 Katherine A. High Induction of tolerance to a therapeutic polypeptide
US20040142893A1 (en) * 2002-10-21 2004-07-22 Uichi Ikeda Methods for treating and preventing vascular disease
US7261882B2 (en) * 2003-06-23 2007-08-28 Reagents Of The University Of Colorado Methods for treating neuropathic pain by administering IL-10 polypeptides
EP1901769A2 (en) 2005-05-02 2008-03-26 Avigen, Inc. Use of cytokine-derived peptides in treatment of pain and neurodegenerative disease
ATE452908T1 (de) 2005-05-31 2010-01-15 Univ Colorado Il-10 mutante

Also Published As

Publication number Publication date
US20090208563A1 (en) 2009-08-20
EP1885863B1 (en) 2014-11-19
WO2006130581A3 (en) 2007-03-22
SI2816118T1 (sl) 2019-01-31
EP2816118B1 (en) 2018-10-17
ES2696824T3 (es) 2019-01-18
EP2816118A1 (en) 2014-12-24
PL2816118T3 (pl) 2019-03-29
LT2816118T (lt) 2018-12-10
US20130337556A1 (en) 2013-12-19
HK1117871A1 (en) 2009-01-23
HUE041875T2 (hu) 2019-06-28
DK2816118T3 (en) 2018-12-03
WO2006130581A2 (en) 2006-12-07
US8524678B2 (en) 2013-09-03
PT2816118T (pt) 2018-11-28
EP1885863A2 (en) 2008-02-13

Similar Documents

Publication Publication Date Title
CY1120856T1 (el) Μεθοδοι παραδοσης γονιδιων
AU2017313917B2 (en) CRISPR-Cas genome engineering via a modular AAV delivery system
Park et al. piggyBac transposition into primordial germ cells is an efficient tool for transgenesis in chickens
CL2017002731A1 (es) Adenovirus oncolítico que codifica una proteína b7
CL2020000728A1 (es) Variantes de cápsides de virus adenoasociados y métodos de uso de estas.
CY1121442T1 (el) Βελτιωμενες μεθοδοι για τον καθαρισμο ανασυνδυασμενων φορεων aav
EA200801756A1 (ru) Противогриппозные вакцины, содержащие гемагглютинин и белки матрикса
BR112018002417A2 (pt) animal não humano ou descendente do mesmo ou uma célula de animal, animal suíno, descendente ou célula, célula, descendente, método de reprodução, população de animais, método para aumentar uma resistência de animal, molécula de ácido nucleico, ácido nucleico e ácido nucleico isolado
CL2019003842A1 (es) Vectores virales recombinantes con tropismo modificado y usos de estos para la introducción dirigida de material genético a células humanas.
AR118465A1 (es) Vectores de virus adenoasociados recombinantes
ATE398672T1 (de) Immortalisierte vogelzellinien zur virusproduktion
ATE438414T1 (de) Verfahren und zusammensetzungen zur kontrollierter abgabe von rekombinant parvovirus vektoren
ATE490321T1 (de) Induzierbare sirna expressionskonstrukte zur gezielten genabschaltung
CL2009000190A1 (es) Virus recombinante de la enfermedad de newcastle que comprende un transgen que codifica una citoquina de ave; nucleocapside y genoma de dicho virus; molecula de adn que codifica el genoma y/o antigenoma del virus; celula y composicion que lo comprenden.
PE20210341A1 (es) Composiciones de virus adeno-asociadas para la transferencia de genes pah y metodos de uso de los mismos
PE20230430A1 (es) Composiciones y metodos para modular simultaneamente la expresion de genes
CL2012002900A1 (es) Secuencias de acido nucleico procedente de un virus causante del sindrome de miocardiopatia (cms) en peces; vector; celula huesped; vacuna de adn; proteina recombinante codificada; vacuna recombinante; inmunoensayo para la deteccion de dicho virus; kit de diagnostico; y uso de las mismas.
AR119869A1 (es) Proteína vp1 modificada aislada de la cápside del virus adeno-asociado de serotipo 5 (aav5), cápside y vector basado en la misma
CY1116649T1 (el) Τεχνητη dna αλληλουχια με βελτιστοποιημενη λειτουργια οδηγου σε 5' (5-utr) για βελτιωμενη εκφραση ετερολογων πρωτεϊνων σε φυτα
PE20212076A1 (es) Composiciones de virus adeno-asociado para restaurar la funcion del gen pah y metodos de uso de las mismas
AR073800A1 (es) Tratamiento de la infeccion del virus de la hepatitis c con sobreexpresion de micro rna -196
CL2018002900A1 (es) Construcciones de adn para la fabricación de polipéptidos bioterapéuticos para su uso en vacunas animales y agentes terapéuticos.
ES2618935T3 (es) Parvovirus modificado útil para silenciamiento génico
Ding et al. Preparation of rAAV9 to overexpress or knockdown genes in mouse hearts
EA200802101A1 (ru) Конструкции-"шпильки" р15 и применение